Dynavax(DVAX) - 2024 Q4 - Annual Results

FORM 8-K Filing Information This section provides essential details regarding the Form 8-K filing, including registrant identification, report date, and filing type Registrant and Filing Details This section identifies Dynavax Technologies Corporation as the registrant, detailing the Form 8-K filing date and type - Registrant: Dynavax Technologies Corporation[2] - Date of Report: January 13, 2025[2] - Filing Type: Current Report on Form 8-K[1] Securities Registered and Emerging Growth Status This section lists the company's registered securities on Nasdaq and confirms Dynavax is not an emerging growth company | Title of each class | Symbol(s) | Name of each exchange on which registered | |---|---|---| | Common Stock, $0.001 par value | DVAX | Nasdaq Global Select Market | | Preferred Share Purchase Rights | N/A | Nasdaq Global Select Market | - Registrant is not an emerging growth company[6] Item 2.02 Results of Operations and Financial Condition Dynavax announced preliminary unaudited Q4 and full year 2024 financial highlights, subject to final audit - Dynavax issued a press release on January 13, 2025, announcing preliminary unaudited fourth quarter and full year 2024 financial highlights[7] - The preliminary financial results are based on estimates and are subject to change upon completion of the financial close process and audit[8] - The press release (Exhibit 99.1) is incorporated by reference[7] Item 7.01 Regulation FD Disclosure The company posted an Investor Presentation and clarified that furnished information is not 'filed' for liability purposes - Dynavax posted an Investor Presentation (Exhibit 99.2) on its website under the 'News & Events' tab[9] - The information in this Form 8-K and its exhibits is furnished, not 'filed,' and is not subject to certain liability provisions of the Securities Exchange Act of 1934 or Securities Act of 1933[10] Item 9.01 Financial Statements and Exhibits This section lists the Form 8-K exhibits, including a press release with financial highlights and an investor presentation | Exhibit No. | Description | |---|---| | 99.1 | Press release dated January 13, 2025 titled "Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights." | | 99.2 | Dynavax Investor Presentation. | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures This section confirms the report's due signing by an authorized officer of Dynavax Technologies Corporation - The report was signed by Kelly MacDonald, Senior Vice President, CFO, on January 13, 2025[14]